Singapore markets closed

Aadi Bioscience, Inc. (AADI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.8400+0.0200 (+1.10%)
At close: 04:00PM EDT
1.7800 -0.06 (-3.26%)
After hours: 05:13PM EDT

Aadi Bioscience, Inc.

17383 Sunset Boulevard
Suite A250
Pacific Palisades, CA 90272
United States
424-744-8055
https://aadibio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees75

Key executives

NameTitlePayExercisedYear born
Dr. Neil P. Desai Ph.D.Founder & Executive Chairman710.35kN/A1965
Mr. David J. Lennon Ph.D.President, CEO & Director277.75kN/A1971
Mr. Scott M. Giacobello CPACFO, Treasurer, Investor Relations & Corporate Communications643.23kN/A1970
Dr. Loretta M. Itri F.A.C.P., M.D.Chief Medical Officer617.45kN/A1950
Mr. Stephen M. Rodin J.D.Senior VP of Legal & General CounselN/AN/A1976
Mr. Raymond G. SteitzSenior VP of Human Resources & Chief Human Resources OfficerN/AN/A1959
Mr. Bryan BallChief Quality Officer & Senior VP of Manufacturing OperationsN/AN/A1970
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Corporate governance

Aadi Bioscience, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.